Medicare’s drug pricing negotiations — the first of their kind in the United States, passed under President Joe Biden — face ...

Holiday weight gain hits home for many come January. These days, folks making resolutions to slim down and get fit have an ...

Roche's strategic acquisition of Poseida Pharmaceuticals positions them as a leader in the allogeneic cell therapy market.

Maridebart cafraglutide, a novel injectable GIP receptor antagonist/GLP-1 receptor agonist, reduced body weight by ...

The drug's development was funded by Novo Nordisk, the maker of popular semaglutide drugs like Ozempic and Wegovy. While these GLP-1 receptor agonists are effective in weight management, they often ...

How GLP-1 therapies could help build a healthier, more productive workforce—and what that would mean for how we live together ...

Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.

Trump could keep Biden’s commitment to have Medicare pay for weight loss drugs such as Ozempic and Wegovy. But would ...

On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a declaratory order determining that the shortage of diabetes and ...

On its way out the door, the Biden administration is proposing that Medicare and Medicaid cover Ozempic and other GLP-1 drugs ...